1. Αρχική σελίδα
  2. Αναζήτηση

Long-acting somatostatin analogues are an effective treatment for type 1 gastric carcinoid tumours

Το τεκμήριο παρέχεται από τον φορέα :
National Technical University of Athens   

Αποθετήριο :
Digital Library of National Technical University of Athens | Dspace@NTUA   

δείτε την πρωτότυπη σελίδα τεκμηρίου
στον ιστότοπο του αποθετηρίου του φορέα για περισσότερες πληροφορίες και για να δείτε όλα τα ψηφιακά αρχεία του τεκμηρίου*



Long-acting somatostatin analogues are an effective treatment for type 1 gastric carcinoid tumours (EN)
Grozinsky-Glasberg, S (EN)
Kaltsas, G (EN)
Fichman, S (EN)
Thomas, D (EN)
Alexandraki, K (EN)
Gross, DJ (EN)
Gur, C (EN)
Barak, D (EN)
Shimon, I (EN)
Glaser, B (EN)
Gal, E (EN)
journalArticle (EN)
2014-03-01T01:57:26Z
2008 (EN)
Background: Gastric carcinoid tumours type 1 (GCA1) originate from hyperplastic enterochromaflin-like (ECL) cells secondary to hypergastrinaemia. Treatment with somatostatin analogues (SSA) might impede ECL-cell hyperplasia by suppressing gastrin secretion and/or by a direct anti-proliferative effect on ECL cells. We conducted a multicentre prospective study to assess the effects of long-acting SSA on hypergastrinaemia and ECL-cell proliferation in patients with GCA1. Methods: We studied 15 patients with GCA1 treated with monthly long-acting release octreotide (LAR) (20-30 mg; n = 14) or Lanreotide 90 mg (n = 1) for at least 6 months. Patients had serum gastrin and chromogranin A measurements performed and biopsies taken from both tumours and surrounding mucosa before. and every 6-12 months following treatment. Sections were immunostained for neuroendocrine markers. The cell proliferation index Ki-67, intensity of staining before and after treatment and the degree of gastric wall invasion were also assessed. Results: All patients tolerated treatment well (mean follow-up of 18 months). In 11 patients (73%), a complete disappearance of the tumours at 1 year of treatment was observed on endoscopy, while in normalized in 25% of patients, and were reduced by more than 80% in the remaining 75%. Conclusions: Treatment with SSAs in GCA1 leads to a substantial tumour load reduction, with a concomitant decrease of serum gastrin levels. Our data indicate an important anti-proliferative effect of SSA on ECL cells, providing clinical benefit and obviating, at least temporarily, the need for invasive therapies for GCA1. (EN)
Endocrinology & Metabolism (EN)
ECL CELL (EN)
OCTREOTIDE (EN)
NEUROENDOCRINE TUMORS (EN)
MANAGEMENT (EN)
ENDOCRINE CELL HYPERPLASIA (EN)
ATROPHIC GASTRITIS (EN)
ANTRECTOMY (EN)
DYSPLASIA (EN)
PERNICIOUS-ANEMIA (EN)
HYPERGASTRINEMIC PATIENTS (EN)
EUROPEAN JOURNAL OF ENDOCRINOLOGY (EN)
Αγγλική γλώσσα
BIO SCIENTIFICA LTD (EN)
National Technical University of Athens
Digital Library of National Technical University of Athens | Dspace@NTUA
Κεντρική Βιβλιοθήκη Ε.Μ.Π.
Ιδρυματικό Αποθετήριο
Δημοσιεύσεις μελών Δ.Ε.Π. σε περιοδικά



*Η εύρυθμη και αδιάλειπτη λειτουργία των διαδικτυακών διευθύνσεων των συλλογών (ψηφιακό αρχείο, καρτέλα τεκμηρίου στο αποθετήριο) είναι αποκλειστική ευθύνη των αντίστοιχων Φορέων περιεχομένου.